Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PRAME Antibodies:
anti-Mouse (Murine) PRAME Antibodies:
anti-Rat (Rattus) PRAME Antibodies:
Go to our pre-filtered search.
Polyclonal PRAME Primary Antibody for WB - ABIN540326
Steinbach, Hermann, Viehmann, Zintl, Gruhn: Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. in Cancer genetics and cytogenetics 2002
Cow (Bovine) Polyclonal PRAME Primary Antibody for WB - ABIN2786466
Sakakura, Kubo, Ako, Ikeda, Funayama, Hirahara, Sugawara, Yasu, Kawakami, Momomura: Determinants of in-hospital death and rupture in patients with a Stanford B aortic dissection. in Circulation journal : official journal of the Japanese Circulation Society 2007
Show all 2 Pubmed References
Cow (Bovine) Polyclonal PRAME Primary Antibody for WB - ABIN2786465
Roman-Gomez, Jimenez-Velasco, Agirre, Castillejo, Navarro, Jose-Eneriz, Garate, Cordeu, Cervantes, Prosper, Heiniger, Torres: Epigenetic regulation of PRAME gene in chronic myeloid leukemia. in Leukemia research 2007
Show all 2 Pubmed References
the expansion of the PRAME family occurred in both autosomes and sex chromosomes
PRAME is frequently expressed in epithelial ovarian cancer at the mRNA and protein levels, and DNA methylation (show HELLS Antibodies) is a key mechanism regulating its expression.
PRAME is aberrantly hypomethylated and activated in Class 1 and Class 2 uveal melanomas and is associated with increased metastatic risk in both classes
To investigate the impact of gene copy number variation on PRAME expression, plasma cells were sorted from 50 newly diagnosed multiple myeloma patients and 8 healthy volunteers to measure PRAME transcript levels and gene copy numbers by real-time quantitative polymerase chain reaction.
Tumor antigen PRAME is up-regulated by MZF1 (show ZFP42 Antibodies) in cooperation with DNA hypomethylation in melanoma cells.
Results support the potential utility of NY-ESO-1 (show CTAG1B Antibodies), PRAME, and MAGEA4 (show MAGEA4 Antibodies) as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas.
PRAME plays a role in preventing the invasion and metastasis of lung adenocarcinoma
PRAME is expressed in many primary and metastatic UMs (show TBX3 Antibodies), and about half of the metastatic UMs (show TBX3 Antibodies) coexpress PRAME and HLA class I (show MICA Antibodies).
PRAME is a downstream factor of SOX17 (show SOX17 Antibodies) and LIN28 (show LIN28A Antibodies) in regulating pluripotency and suppressing somatic/germ cell differentiation in primordial germ cells, germ cell neoplasia in situ, and seminomas.
In line with its roles in controlling cell growth, RPAME regulates multiple critical cell-growth related genes, including IGF1R (show IGF1R Antibodies) oncogene (show RAB1A Antibodies). IGF1R (show IGF1R Antibodies) up-regulation contributes to increase of cell growth upon the knockdown of PRAME.
This study demonstrates that PRAME functions as a tumor suppressor in breast cancer.
This gene encodes an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. Five alternatively spliced transcript variants encoding the same protein have been observed for this gene.
preferentially expressed antigen in melanoma
, Opa-interacting protein OIP4
, cancer/testis antigen 130
, melanoma antigen preferentially expressed in tumors
, opa-interacting protein 4
, preferentially expressed antigen of melanoma